Project Title:
Multi-Center Group to Study Acute Liver Failure (ALF). Long-term Outcomes of ALF Patients
Purpose:
To prospectively obtain tissue and blood samples from patients with ALF and encephalopathy. The present study will allow an in-depth analysis of cases of acute liver failure from 40 centers around the United States in the ALF Study Group (ALFSG), with an emphasis on the cause, and eventually, on the treatment of this puzzling yet devastating condition.
Sponsor:
NIH/NIDDK
Principal Investigator:
Andres T. Blei, MD
Cost:
None
Contact:
Jeanne Gottstein, (312) 908-5902
IRB Project Number: 0126-008
Project Title:
Probiotics: A New Approach To Correct Intestinal Permability Of Patients With Cirrhosis Awaiting Liver Transplant
Purpose:
Primary Aim: To determine the effect of 30 day administration of probiotics on intestinal permeability (lactulose/mannitol test) in patients with cirrhosis and ascites.
Sponsor:
PI Initiated
Principal Investigator:
Josh Levitsky, M.D.
Cost:
None
Contact:
Jeanne Gottstein, (312) 908-5902
IRB Project Number: 1783-001
Project Title:
The Early Use of Sanvar® with Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension
Purpose:
Primary Objective: To determine the efficacy of the early administration of Sanvar(r) (vapreotide) in association with endoscopic treatment for the control of bleeding at 5 days, i.e. control of initial bleeding and prevention of early re-bleeding, plus survival. These results will be evaluated for clinical significance in light of the efficacy results achieved in the vapreotide pivotal trial and the results reported in the available literature on octreotide.
Secondary Objective: To assess the following: The effect of drug administration before endoscopy assessed by the endoscopic facilitation and control of bleeding at endoscopy, Control of bleeding 6 hours after infusion of the study drug, Control of bleeding by time periods and by Child Pugh class, number of blood units administered during the 5 days of drug infusion, and safety of treatment.
Sponsor:
Debiovision
Principal Investigator:
Andres T. Blei, MD
Cost:
None
Contact:
Jeanne Gottstein, (312) 908-5902
IRB Project Number: 0126-027
